The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer
- PMID: 38039967
- DOI: 10.1016/j.immuni.2023.11.002
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer
Abstract
In triple-negative breast cancer (TNBC), stromal restriction of CD8+ T cells associates with poor clinical outcomes and lack of responsiveness to immune-checkpoint blockade (ICB). To identify mediators of T cell stromal restriction, we profiled murine breast tumors lacking the transcription factor Stat3, which is commonly hyperactive in breast cancers and promotes an immunosuppressive tumor microenvironment. Expression of the cytokine Chi3l1 was decreased in Stat3-/- tumors. CHI3L1 expression was elevated in human TNBCs and other solid tumors exhibiting T cell stromal restriction. Chi3l1 ablation in the polyoma virus middle T (PyMT) breast cancer model generated an anti-tumor immune response and delayed mammary tumor onset. These effects were associated with increased T cell tumor infiltration and improved response to ICB. Mechanistically, Chi3l1 promoted neutrophil recruitment and neutrophil extracellular trap formation, which blocked T cell infiltration. Our findings provide insight into the mechanism underlying stromal restriction of CD8+ T cells and suggest that targeting Chi3l1 may promote anti-tumor immunity in various tumor types.
Keywords: Chi3l1; NETosis; T cell stromal restriction; TNBC; breast cancer; immune microenvironment; immunotherapy; mouse models; neutrophils.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.A.E. is a co-founder of Elkurt Therapeutics and is a founder of and stockholder in and serves on the Scientific Advisory Board for Ocean Biomedical Inc., which develops inhibitors of 18-glycosyl hydrolases as therapeutics. C.G.L. and S.K. are consultants for Ocean Biomedical Inc. J.A.E., C.G.L., and S.K. have a patent entitled “methods and composition relating to anti-CHI3L1 antibody reagents” (US Patent 10253111).
Comment in
-
Chi3l1: New kid on the T cell blockade.Immunity. 2023 Dec 12;56(12):2672-2674. doi: 10.1016/j.immuni.2023.11.015. Immunity. 2023. PMID: 38091946
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous
